These observations were similar to our published findings where we observed that HDAC9 expression was 500- and 50-fold higher in BRM-deficient lung cancer cell lines and BRM-deficient primary lung tumors, respectively, compared to BRM-positive lung cancer cell lines and primary tumors [25]. This evidence concerns the gene HDAC9 and lung cancer.